---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-22-000099"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:31:47.012263+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio Q3 2022 net loss $59.4M; cash $304.4M; TORREY topline expected Nov/Dec

## Summary
- Net loss $59.4M ($0.65/shr) vs $60.2M ($0.80/shr) in Q3 2021; cash $304.4M sufficient into Q2 2024.
- R&D expenses $44.5M, G&A $11.5M for quarter ended Sep 30, 2022.
- Phase 2 TORREY topline data for seralutinib expected in second half of Nov or first half of Dec 2022.
- Enrollment ongoing in Phase 1b/2 STAR CNS study of GB5121 for relapsed/refractory CNS lymphomas.
- Preclinical pipeline updates presented at multiple medical conferences; three internally developed programs.

## SEC filing metadata
- accession: 0001728117-22-000099
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811722000099/0001728117-22-000099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811722000099/goss-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-22-000099
- JSON: https://secwatch.observer/filing/0001728117-22-000099.json
- Plain text: https://secwatch.observer/filing/0001728117-22-000099.txt

## Key facts
- Earnings Releases
  Gossamer Bio, Inc. reported third quarter ended September 30, 2022 results: net income Net loss for the quarter ended September 30, 2022, was $59.4 million, or $0.65 per share, EPS $0.65 per share.
  - Period: third quarter ended September 30, 2022
  - Net income: Net loss for the quarter ended September 30, 2022, was $59.4 million, or $0.65 per share
  - EPS: $0.65 per share
  - Result: reported results
  source text: Gossamer Bio, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728117/000172811722000099/0001728117-22-000099-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.